Racial and Gender Discrimination When Tailoring Medical Management to Hypertension Treatment in Latin America

Luis Alcocer1, Ernesto L Schiffrin2, Gregory Fink3

  • 1Instituto Mexicano de Salud Cardiovascular, Ciudad de México, México.

Insights

Discrimination in hypertension treatment in Latin America affects women, minorities, and the poor. Addressing gender, ethnic, and economic biases is crucial for equitable cardiovascular healthcare and improved health outcomes.

Area of Science:

  • Cardiovascular medicine
  • Public health
  • Health equity

Background:

  • Cardiovascular disease (CVD) is a leading global cause of death.
  • Significant disparities persist in cardiovascular healthcare delivery in Latin America.
  • Marginalized populations, including women, ethnic minorities, and low-income groups, face substantial barriers to care.

Purpose of the Study:

  • To highlight the complex issue of discrimination in hypertension treatment in Latin America.
  • To identify key drivers of these disparities: gender, ethnicity, and economic status.
  • To advocate for strategies that ensure equitable access and quality of care for all populations.

Main Methods:

  • Analysis of existing literature and data on cardiovascular healthcare disparities in Latin America.
  • Review of socio-economic and ethnic factors influencing hypertension treatment.
  • Endorsement of consensus recommendations addressing personalized care, racial bias, socioeconomic inequalities, and gender disparities.

Main Results:

  • Women, ethnic minorities, and economically disadvantaged individuals experience underrepresentation in research, delayed diagnoses, and unequal access to recommended treatments.
  • Economic status directly correlates with healthcare quality, exacerbating inequities for lower-income communities.
  • Ethnic discrimination leads to inadequate care and limited access to advanced medical technologies for indigenous and Afro-descendant populations.

Conclusions:

  • Comprehensive strategies are needed to dismantle biases, improve access for disadvantaged communities, and ensure equal quality of care for ethnic minorities.
  • Equitable participation in clinical trials and culturally sensitive public health policies are essential.
  • Removing discriminatory barriers is vital to reduce the burden of cardiovascular disease and enhance health outcomes across Latin America.

Related Concept Videos

Hormonal Regulation01:33

Hormonal Regulation

The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
32.8K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
331
Hypertension and Regulation of Blood Pressure01:18

Hypertension and Regulation of Blood Pressure

Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
1.8K
Errors occurring during blood pressure monitoring01:25

Errors occurring during blood pressure monitoring

Blood pressure monitoring is a crucial clinical procedure in diagnosing and managing various cardiovascular conditions. Despite its significance, the accuracy of blood pressure measurements can be compromised by multiple factors, potentially leading to either falsely high or low readings. These inaccuracies are critical as they can significantly impact patient care. So, it is vital to understand these challenges deeply and adopt strategic approaches to minimize errors.
Several factors...
573
Alterations in Blood Pressure01:30

Alterations in Blood Pressure

Alterations in blood pressure, such as hypertension (high blood pressure) and hypotension (low blood pressure), significantly affect human health. Understanding these conditions' classifications, causes, and symptoms is essential for effective management and treatment.
Hypertension (High blood pressure)
Hypertension occurs when blood pressure readings consistently exceed the normal range. It is diagnosed when systolic blood pressure (the top number, indicating pressure while the heart...
1.2K
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
393